Objective: To assess preoperative parameters that may be predictive of pathologic stage T2a disease in low-risk prostate cancer patients. Methods: Data from a cohort of 1,495 consecutive men with low-risk prostate cancer who underwent a radical prostatectomy between 1993 and 2009 were evaluated. Preoperative parameter assessment focused on age, race, clinical stage, diagnostic PSA level, biopsy tumor laterality and diagnostic Gleason score. Preoperative parameters were analyzed by univariate and multivariate methods. Kaplan-Meier method was used to evaluate the biochemical disease-free survival. Results: Among the 1,495 men, 236 (15.8%) had pT2a disease. In univariate analysis, biopsy tumor unilaterality (p < 0.001), diagnostic PSA ≤4 ng/ml (p < 0.001) and non-African-American race (p = 0.009) were significant variables. In multivariate analysis, biopsy tumor laterality (OR 0.377; p < 0.001), diagnostic PSA ≤4 ng/ml (OR 0.621; p = 0.002) and race (OR 0.583; p = 0.029) were independent predictors. Low-risk patients with pT2a disease showed a better PSA recurrence-free survival rate, compared with men with >pT2a diseases (p = 0.012). Conclusions: Biopsy tumor unilaterality, diagnostic PSA ≤4 ng/ml and race are independent predictors of pT2a in low-risk prostate cancer. These three preclinical variables may be a useful reference to begin the selection process for focal therapy in men with low-risk prostate cancer.

Keywords:
Prostate cancer, Pathological stage, Gleason score, Low-risk disease, Focal therapy
1.
Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ: Prostate cancer: the new landscape. Curr Opin Urol 2009;19:154–160.
2.
Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14–S19.
3.
Carroll PR: Early stage prostate cancer – do we have a problem with overdetection, overtreatment or both? J Urol 2005;173:1061–1062.
4.
Harlan SR, Cooperberg MR, Elkin EP, Lubeck DP, Meng MV, Mehta SS, et al: Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003;170:1804–1807.
5.
Polascik TJ, Mayes JM, Mouraviev V: Nerve-sparing focal cryoablation of prostate cancer. Curr Opin Urol 2009;19:182–187.
6.
Polascik TJ, Mayes JM, Schroeck FR, Sun L, Madden JF, Moul JW, et al: Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 2009;115:2104–2110.
7.
Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110:906–910.
8.
Tareen B, Godoy G, Sankin A Temkin S, Lepor H, Taneja SS: Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. J Urol 2009;18:1082–1089.
9.
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.
10.
Lambert EH, Bolte K, Masson P, Katz AE: Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology 2007;69:1117–1120.
11.
Onik G, Vaughan D, Lotenfoe R, Dineen M, Brady J: The ‘male lumpectomy’: focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008;26:500–505.
12.
Tareen B, Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS: Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort. Urology 2009;73:351–354.
13.
Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 2008;68:1380–1386.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.